How Common Is Vomiting with Lurbinectedin?
Lurbinectedin (Zepzelca), used for metastatic small cell lung cancer, commonly causes nausea and vomiting. Clinical trial data show vomiting in 37% of patients overall, with severe (grade 3-4) cases in 3%.[1] Nausea occurs in 57% overall and 4% severely.[1]
Why Does Vomiting Happen and When?
Vomiting stems from lurbinectedin's effects on rapidly dividing cells in the gut, similar to other chemotherapy agents. It typically starts within days of infusion and peaks early in treatment cycles. Premedication with antiemetics like dexamethasone, 5-HT3 antagonists (e.g., ondansetron), and NK1 inhibitors (e.g., aprepitant) reduces incidence by over 50% in trials.[1][2]
How Does It Compare to Other Chemotherapy Side Effects?
Vomiting ranks among the top gastrointestinal issues, behind nausea but ahead of diarrhea (20%) and constipation (15%). Fatigue (60%) and hematologic effects like neutropenia (60%) are more frequent overall.[1] In combination with other drugs, rates can rise slightly.
What Do Patients Report About Managing It?
Patients often describe vomiting as manageable with standard antiemetic regimens, but breakthrough cases occur in 10-20% despite prophylaxis. Hydration, small frequent meals, and avoiding strong odors help. Dose delays or reductions happen in under 5% due to vomiting alone.[2][3]
Are There Long-Term or Delayed Risks?
Acute vomiting resolves post-cycle, but chronic nausea affects 10-15% over multiple cycles. No strong link to permanent gut damage, though electrolyte imbalances from severe vomiting require monitoring.[1]
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, FDA-approved label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[2]: Trigo et al., Lurbinectedin monotherapy efficacy in SCLC, Lancet Oncology (2019). https://pubmed.ncbi.nlm.nih.gov/30851942/
[3]: Paz-Ares et al., Lurbinectedin Phase II trial data, J Clin Oncol (2020). https://pubmed.ncbi.nlm.nih.gov/32324429/